Exicure to Sell GPC-100 Program to GPCRT for ~US$4.8M Cash
XCUR sits 39% above its 52-week low of $0.777 on elevated volume (2.7× avg).
Summary
Exicure agreed to sell its GPC-100 program assets to Korea-based GPCRT Inc. for KRW 6.5 billion (~US$4.8M) in cash, with KRW 2.0 billion due by November 16, 2026 and the rest at closing. The deal offloads future program obligations but leaves Exicure with pre-September 2026 liabilities and a going-concern overhang.
Key Events · M&A and Partnerships · XCUR
-
GPC-100 Program Sold for ~US$4.8M
Exicure and GPCR USA agreed on November 4, 2026 to sell the GPC-100 (burixafor) assets — the License and Collaboration Agreement rights, IP, clinical data, materials and equipment — to GPCRT Inc. for KRW 6,500,000,000 (approximately US$4.8 million), payable entirely in cash.
-
Payment Schedule and Cash Timing
KRW 500 million was already paid as a deposit and is credited against the price; KRW 2.0 billion is due on or before November 16, 2026; the final KRW 4.0 billion is payable at closing. That is roughly US$1.5M near-term and US$3.0M at close, against $1.7M of cash reported in the August 10-Q.
-
Buyer Assumes Future Obligations
GPCRT assumes the License Agreement obligations from closing, including future milestone and royalty payments, and bears GPC-100 program costs incurred on or after September 1, 2026. Exicure and GPCR USA retain all liabilities incurred before that date, including unpaid Medpace CRO fees of US$644,383.49 and US$782,897.71 of open Dren Bio sublease obligations.
-
Closing Conditions and Stockholder Vote
Closing requires board approvals, regulatory approvals, material third-party consents, a GPCR waiver and release of any claim to the purchase price, and any stockholder approval required under law, charter documents, Nasdaq rules or contracts. No assurance is given that the deal closes.
Analysis · XCUR · Life Sciences
Exicure is selling essentially its only clinical program — the GPC-100 (burixafor) assets it acquired with GPCR USA in January 2025 — for KRW 6.5 billion (~US$4.8 million) in cash. Against a $1.7M cash balance and a going-concern warning disclosed in the August 10-Q, the money matters: KRW 2.0 billion (~US$1.5M) is due by November 16, 2026 and the remaining KRW 4.0 billion (~US$3.0M) at closing. The trade-off is that the buyer takes the future milestone and royalty obligations and program costs from September 1, 2026 onward, but Exicure keeps everything incurred before that date — including roughly US$644K of unpaid Medpace CRO fees and US$783K of open Dren Bio sublease obligations listed as excluded liabilities. Closing is not assured: it needs a GPCR waiver and release, regulatory approvals, third-party consents and any stockholder approval, and the company itself warns it may have limited or no operating business afterward.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XCUR was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.78 to $9.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.